Table 2.
Data collection stages
| Phase 1 Eligibility Questionnaire, self-completed on paper. Reminder sent 2 weeks after initial mailing. |
|---|
| Questions addressing the inclusion and exclusion criteria (Additional file 1) |
| Phase 2.1 Baseline Survey, self-completed on line or on paper as allocated. Reminder sent 2 weeks after initial mailing. |
| Demographic characteristics |
| Age, sex, education, country of birth, marital status, employment status |
| PAPM stage |
| Decision stage for screening assessed by PAPM stage (never heard of FOBT, aware but not engaged, decided not to act, undecided, decided to act) |
| PHM constructs |
| Scores assessed on salience and coherence, cancer worries, response efficacy, social influence, perceived susceptibility [18] |
| Self efficacy |
| Score assessed on confidence to use an FOBT at home |
| Faecal aversion |
| Score assessed on distaste or embarrassment toward handling of faeces |
| Phase 2.2 Invitation to screen, including FOBT. Sent 2-4 weeks after completion of baseline survey with reminder sent 6 weeks after initial invitation. |
| Receipt or non-receipt of completed FOBT recorded by the Bowel Health Service (BHS), Repatriation General Hospital |
| Return of kit |
| Date of return of kit |
| Number of participants who contact the 'help line' provided as part of the standard BHS protocol |
| Phase 3.1 Endpoint Survey, self-completed on line or on paper as allocated. Administered 1-2 weeks following receipt of completed FOBT, or 12 weeks following invitation to screen. Reminder sent 2 weeks after initial mailing. |
| PAPM stage |
| PHM construct scores |
| Self efficacy score |
| Faecal aversion score |
| Participation in any other bowel cancer screening activity since entry into trial |
| Familial history of bowel cancer |
| Usefulness of the educational material |
| Satisfaction with content and ease of navigation (PDS arms) |
| Decisional satisfaction and conflict. Scores assessed by the Decisional Conflict scale [32] |
| Level of motivation to screen. Scores assessed by the Treatment Self-Regulation Questionnaire [33] |
| Phase 3.2 Qualitative data, obtained following Endpoint Survey from telephone interviews with a subset of participants in each arm. |
| Reasons for choosing to participate or not in screening |
| Usefulness of materials |
| How the interventions might be improved |